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Background:  Fractional flow reserve (FFR) assessment during invasive coronary angiography (ICA) improves patient outcomes when 
used for percutaneous coronary intervention guidance (PCI). FFR can now be measured non-invasively by coronary computed tomography 
angiography (CTA) images (FFR-CTA). The diagnostic performance of FFR-CTA has been tested in two large studies (DeFACTO and 
NXT) but its potential value in clinical decision making is unknown. Our aim was to investigate the projected cost of using FFR-CTA as a 
gatekeeper to the catheterization laboratory in patients with suspected coronary artery disease (CAD).
methods:  With published data, a decision-analytic model was developed to simulate costs related to initial management and 1-year 
clinical outcomes (death/myocardial infarction) in patients with suspected stable CAD. Two strategies were simulated: (i) initial assessment 
with CTA-FFR, and patients with CTA-FFR≤0.80 proceeding to ICA and FFR-guided PCI; and (ii) initial assessment with ICA followed by 
FFR-guided PCI (i.e. PCI when FFR≤0.80) considered as the reference standard. Diagnostic performance of CTA-FFR was derived from 
the DeFACTO (252 patients) and NXT (254 patients) studies; the projected cost of the CTA-FFR strategy was modeled twice using the 
data of each study separately, with the most recent NXT study representing an approach with refinements in the CTA-FFR technology and 
emphasis on CTA image acquisition. Cost data for ICA and FFR-guided PCI were derived from the FAME studies, while we assumed that 
the cost of CTA-FFR would be $1000 per patient.
results:  The projected cost for the first year following assessment of suspected CAD was higher for the reference standard with a mean 
annual cost of $7,714/patient. The CTA-FFR strategy resulted in a lower mean annual cost per patient: $7,318 when using data from the 
DeFACTO study, and $4,866 based on the NXT study with the higher diagnostic performance.
conclusion:  A strategy of using CTA-FFR as a gatekeeper to the catheterization laboratory might reduce the cost in patients with 
suspected stable CAD. The cost benefit is substantially larger with enhanced image data acquisition and latest CTA-FFR technology 
refinements.
